Last reviewed · How we verify
ACA Continuation
ACA Continuation works by continuing the effects of ACA.
ACA Continuation works by continuing the effects of ACA. Used for Continuation of ACA treatment.
At a glance
| Generic name | ACA Continuation |
|---|---|
| Sponsor | French Innovative Leukemia Organisation |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ACA Continuation is a continuation of the ACA drug, which means it continues to provide the same effects as the original drug. This is done by maintaining the same mechanism of action, which is to continue the effects of the original drug.
Approved indications
- Continuation of ACA treatment
Common side effects
- Unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACA Continuation CI brief — competitive landscape report
- ACA Continuation updates RSS · CI watch RSS
- French Innovative Leukemia Organisation portfolio CI